Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study With a Limited Safety Lead-In of Enzalutamide in Combination With Carboplatin and Paclitaxel in Advanced Stage or Recurrent Endometrioid Endometrial Cancer

NCT02684227 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.

NCT NCT02684227
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02684227 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study With a Limited Safety Lead-In of Enzalutamide in Combination With Carboplatin and Paclitaxel in Advanced Stage or Recurrent Endometrioid Endometrial Cancer
Lead sponsor
M.D. Anderson Cancer Center
Phase
Phase 2
Overall status
Completed
Start date
August 24, 2016
Completion date
September 27, 2023
Enrollment
50 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent endometrial endometrioid adenocarcinoma, recurrent uterine corpus carcinoma, stage iii uterine corpus cancer ajcc v7, stage iiia uterine corpus cancer ajcc v7, stage iiib uterine corpus cancer ajcc v7, stage iiic uterine corpus cancer ajcc v7, stage iv uterine corpus cancer ajcc v7, stage iva uterine corpus cancer ajcc v7, stage ivb uterine corpus cancer ajcc v7